Drug-resistant tuberculosis: What are the treatment options?

Drugs

Volumn 71, Issue 7, 2011, Pages 815-825

  Albanna, Amr S ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Antimicrobial resistance; Capreomycin; Cycloserine; Ethambutol; Ethionamide; Fluoroquinolones; Isoniazid; Pyrazinamide; Rifabutin; Rifampicin; Streptomycin; Terizidone; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIVIRUS AGENT; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; THIOAMIDE; TUBERCULOSTATIC AGENT;

ADD ON THERAPY; BLOOD BRAIN BARRIER; CHROMOSOME MUTATION; CROSS RESISTANCE; DIET SUPPLEMENTATION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LACTATION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL NEUROPATHY; PREGNANCY; PREGNANT WOMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN MANIFESTATION; SOCIAL SUPPORT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79956101974     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585440-000000000-00000     Document Type: Review

References (78)

1. World Health Organization (WHO). Global tuberculosis control: epidemiology, strategy, financing. WHO report 2009 (WHO/HTM/TB/2009.411) [online]. Available from URL: http://www.who.int/tb/publications/global-report/ 2009/en/index.html [Accessed 2011 Mar 2].
2. World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response (WHO/HTM/TB/2010.3) [online]. Available from URL: http://whqlibdoc.who.int/ publications/2010/9789241599191-eng.pdf [Accessed 2011 Mar 2].
3. World Health Organization (WHO). Drug-resistant tuberculosis now at record levels (18 March 2010; Geneva/ Washington, DC) [news release; online]. Available from URL: http://www.who.int/mediacentre/news/releases/2010/ drug-resistant-tb-20100318/en/ [Accessed 2011 Mar 2].
4. Gandhi NR, Moll A, Sturm AW, et al. Extensively drugresistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006 Nov 4; 368 (9547): 1575-1580. (Pubitemid 44780738)
5. Toman K, Frieden TR, Thomas R. Toman's tuberculosis case detection, treatment and monitoring: questions and answers. 2nd ed. (WHO/HTM/TB/2004.334) [online]. Available from URL: http://www.who.int/tb/publications/to man/en/index.html [Accessed 2011 Mar 2].
6. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009 Nov; 13 (11): 1320-1330.
7. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948 Dec 11; 2 (4588): 1009-1015.
8. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIVinfected patients with and without tuberculosis. Clin Infect Dis 2004 Jan 15; 38 (2): 280-283. (Pubitemid 38113038)
9. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998 Jan; 2 (1): 10-15. (Pubitemid 28108937)
10. van Altena R, van Soolingen D, van der Werf TS. Isoniazid resistant TB and non-compliance [letter]. Thorax 2004 Dec; 59 (12): 1098; author reply 1098-099.
11. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.NEngl JMed 1994 Apr 28; 330 (17): 1179-1184. (Pubitemid 24121986)
12. Mathew JL. Fixed dose drug combination for treatment of tuberculosis. Indian Pediatr 2009 Oct; 46 (10): 877-880.
13. March F, Garriga X, Rodríguez P, et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 1997 Nov; 25 (5): 1044-1047. (Pubitemid 27513183)
14. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62 (15): 2169-2183. (Pubitemid 35252827)
15. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008 Nov; 32 (5): 1165-1174.
16. Barnard M, Albert H, Coetzee G, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med 2008 Apr 1; 177 (7): 787-792. (Pubitemid 351490566)
17. World Health Organization (WHO).Treatment of tuberculosis: guidelines - 4th ed. (WHO/HTM/TB/2009.420) [online]. Available from URL: http://www.who.int/ tb/pub lications/tb-treatmentguidelines/en/index.html [Accessed 2011 Mar 2].
18. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2008.402).Emergency update 2008 [online]. Available from URL: http://whqlibdoc.who.int/publications/ 2008/9789241547581-eng.pdf [Accessed 2011 Mar 2].
19. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006 Mar 30; 354 (13): 1352-1361.
20. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006 Feb; 61 (2): 158-163. (Pubitemid 43235434)
21. Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999 Oct; 58 (4): 633-661. (Pubitemid 29520510)
22. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003 Jun 20; 52 (RR-11): 1-77.
23. Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008 Feb; 12 (2): 139-145. (Pubitemid 351212404)
24. Zhong M, Wang Y, Sun C, et al. Growth of rifampindependent Mycobacterium tuberculosis in conditions without rifampin [in Chinese]. Zhonghua Jie He He Hu Xi Za Zhi 2002 Oct; 25 (10): 588-590.
25. Zhong M, Zhang X, Wang Y, et al. An interesting case of rifampicin-dependent/-enhanced multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2010 Jan; 14 (1): 40-44.
26. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003 Jan 9; 348 (2): 119-128. (Pubitemid 36056718)
27. Louw GE, Warren RM, Donald PR, et al. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006 Jul; 10 (7): 802-807. (Pubitemid 44031396)
28. Mphahlele M, Syre H, Valvatne H, et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008 Oct; 46 (10): 3459-3464.
29. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2006.361) [online]. Available from URL: http://whqlibdoc.who.int/publications/2006/9241546956- eng.pdf [Accessed 2011 Mar 2].
30. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010 Sep; 10 (9): 621-629.
31. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and survival based on drug resistance patterns in multidrugresistant tuberculosis. Am J Respir Crit Care Med 2010 Jul 1; 182 (1): 113-119.
32. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008 Mar; 52 (3): 852-857. (Pubitemid 351358362)
33. Kennedy N, Berger L, Curram J, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin Infect Dis 1996 May; 22 (5): 827-833. (Pubitemid 26255603)
34. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008 Jan 23; (1): CD004795.
35. Alangaden GJ, Manavathu EK, Vakulenko SB, et al. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995 Aug; 39 (8): 1700-1703.
36. Kam KM, Yip CW, Cheung TL, et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Resist 2006 Spring; 12 (1): 7-11.
37. Cheng AF, Yew WW, Chan EW, et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004 Feb; 48 (2): 596-601. (Pubitemid 38141721)
38. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003 Oct; 124 (4): 1476-1481. (Pubitemid 37290060)
39. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drugresistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010 May 22; 375 (9728): 1798-1807.
40. Morlock GP, Metchock B, Sikes D, et al. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003 Dec; 47 (12): 3799-3805. (Pubitemid 37484992)
41. Warren RM, Streicher EM, Gey van Pittius NC, et al. The clinical relevance of Mycobacterial pharmacogenetics. Tuberculosis (Edinb) 2009 May; 89 (3): 199-202.
42. Lew W, Pai M, Oxlade O, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008 Jul 15; 149 (2): 123-134. (Pubitemid 352008599)
43. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 2009 Sep; 6 (9): e1000146.
44. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009 Sep 9; 4 (9): e6914.
45. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009 Mar; 9 (3): 153-161.
46. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009 Aug 1; 180 (3): 273-280.
47. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-279. (Pubitemid 29481843)
48. Hannan MM, Desmond EP, Morlock GP, et al. Pyrazinamide- monoresistant Mycobacterium tuberculosis in the United States. J Clin Microbiol 2001 Feb; 39 (2): 647-650. (Pubitemid 32150834)
49. US Standard from the National Committee for Clinical Laboratory Standards. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes; approved standard, M24-A. Wayne (IN): NCCLS, 2003.
50. Tenover FC, Crawford JT, Huebner RE, et al. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993 Apr; 31 (4): 767-770. (Pubitemid 23086511)
51. Caminero JA. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 2006 Aug; 10 (8): 829-837. (Pubitemid 44197841)
52. Van Deun A, Salim MA, Das AP, et al. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004 May; 8 (5): 560-567. (Pubitemid 38656041)
53. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug- resistant tuberculosis. Am J Respir Crit Care Med 2010 Sep 1; 182 (5): 684-692.
54. Tsukamura M, Mizuno S. Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis. J Gen Microbiol 1975 Jun; 88 (2): 269-274.
55. Chambers HF, Kocagö z T, Sipit T, et al. Activity of amoxicillin/ clavulanate in patients with tuberculosis. Clin Infect Dis 1998 Apr; 26 (4): 874-877.
56. Jagannath C, Reddy MV, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995 Apr; 151 (4): 1083-1086.
57. Luna-Herrera J, Reddy VM, Daneluzzi D, et al. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995 Dec; 39 (12): 2692-2695.
58. The Collaborative Group for Meta-Analysis of Individual Patient Data in Multi-drug Resistant Tuberculosis (MDR TB). Evidence for new MDR TB treatment recommendations [oral presentation]. North American Region Meeting of the International Union Against Tuberculosis And Lung Disease; 2011 Feb 24-26; Vancouver (BC).
59. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009 Apr; 33 (4): 871-881.
60. Kim SJ, Espinal MA, Abe C, et al. Is second-line antituberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004 Sep; 8 (9): 1157-1158. (Pubitemid 39201267)
61. Dheda K, Warren RM, Zumla A, et al. Extensively drugresistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am 2010 Sep; 24 (3): 705-725.
62. Duff P. Antibiotic selection in obstetric patients. Infect Dis Clin North Am 1997 Mar; 11 (1): 1-12. (Pubitemid 27182267)
63. Drobac PC, del Castillo H, Sweetland A, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to secondline agents. Clin Infect Dis 2005 Jun 1; 40 (11): 1689-1692. (Pubitemid 40720824)
64. Mukherjee JS, Joseph JK, Rich ML, et al. Clinical and programmatic considerations in the treatment ofMDR-TB in children: a series of 16 patients from Lima, Peru. Int J Tuberc Lung Dis 2003 Jul; 7 (7): 637-644. (Pubitemid 36806858)
65. Drobac PC, Mukherjee JS, Joseph JK, et al. Communitybased therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006 Jun; 117 (6): 2022-2029. (Pubitemid 46071247)
66. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991 Mar 16; 337 (8742): 627-630.
67. Watkins WM, Mungai M, Muhia DK, et al. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma. Br J Clin Pharmacol 1996 Feb; 41 (2): 160-162. (Pubitemid 26059129)
68. Breen RA, Lipman MC, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals [letter]. AIDS 2000 Mar 31; 14 (5): 615. (Pubitemid 30209704)
69. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002 Jan 4; 16 (1): 75-83. (Pubitemid 34062184)
70. Marks DJ, Dheda K, Dawson R, et al. Adverse events to antituberculosis therapy: influence of HIV and antiretroviral drugs. Int J STD AIDS 2009 May; 20 (5): 339-345.
71. Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1985 Nov-Dec; 10 (6): 532-534. (Pubitemid 16236839)
72. Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of patients with multidrug- resistant tuberculosis. Int J Tuberc Lung Dis 2001 Apr; 5 (4): 321-328. (Pubitemid 32397582)
73. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011 Jan 8; 377 (9760): 147-152.
74. O'Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med 2010 Oct 19; 153 (8): 516-522.
75. Jarand J, Shean K, O'Donnell M, et al. Extensively drugresistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health 2010 Oct; 15 (10): 1179-1184.
76. Papastavros T, Dolovich LR, Holbrook A, et al. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002 Jul 23; 167 (2): 131-136. (Pubitemid 34791519)
77. Ridzon R, Meador J, Maxwell R, et al. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997 Jun; 24 (6): 1264-1265. (Pubitemid 27249040)
78. Pomerantz BJ, Cleveland Jr JC, Olson HK, et al. Pulmonary resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc Surg 2001 Mar; 121 (3): 448-453. (Pubitemid 32230212)